Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aqueous native ragweed pollen allergen is an allergen extract derived from ragweed pollen, primarily used for allergy immunotherapy to induce tolerance in individuals with ragweed pollen-induced allergic rhinitis, with or without conjunctivitis. The mechanism of action involves modulating the immune response—primarily by promoting immune tolerance—through repeated exposure to the allergen. The principal active component is Amb a 1, the major ragweed pollen allergen, which stimulates immunological changes, notably shifting the response away from IgE-mediated hypersensitivity. This product is designed for sublingual or subcutaneous administration as part of medication regimens to prevent or reduce symptoms related to ragweed pollen allergy; it does not provide immediate symptom relief[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aqueous native ragweed pollen allergen.